NUCALA (mepolizumab) injection
Nucala is a brand-name prescription medication. It’s used to treat two conditions: severe eosinophilic asthma in adults and children ages 12 years and older. With this kind of severe asthma, you have high levels of eosinophils (a type of white blood cell). Brand Name: NUCALA (mepolizumab) injection, for subcutaneous use Initial U.S. Approval: 2015
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
NUCALA (mepolizumab) injection
Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES).
NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for:
• Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype.
• Add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP).
• The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
• The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.
Mepolizumab is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of severe asthma in patients aged six years or older and with an eosinophilic phenotype in combination with other medicines used to treat asthma.[6] In the European Union it is approved as an add-on treatment for severe refractory eosinophilic asthma in adults.
In studies, mepolizumab cut the necessity for hospitalisation due to asthma exacerbations in half, as compared to placebo.
In December 2017, the FDA expanded mepolizumab’s indication to treat adults with eosinophilic granulomatosis with polyangiitis, which is a rare autoimmune condition that can cause vasculitis.
In September 2020, the FDA expanded mepolizumab’s indication to treat adults and children aged twelve years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.
Drug (Brand / Generic): NUCALA / mepolizumab
Current Indications: eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES).
Marketed by:: GlaxoSmithKline
Approval Date: 2015
Dosage forms and strengths of NUCALA (mepolizumab) injection
For injection: 100 mg of lyophilized powder in a single-dose vial for reconstitution.
• Injection: 100 mg/mL, single-dose prefilled autoinjector or single-dose prefilled syringe.
• Injection: 40 mg/0.4 mL, single-dose prefilled syringe.
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ NUCALA (mepolizumab) injection ”. Confirmation of the order for NUCALA (mepolizumab) injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – NUCALA
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
NUCALA Sourcing & Delivery
Alleviare India specializes in sourcing and supplying NUCALA, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of NUCALA in India.
How much does NUCALA cost in the India?
Kindly reach out to us for NUCALA (mepolizumab) injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import NUCALA to India?
To import mepolizumab NUCALA, patients or government hospitals can place an order on behalf of the patients. The following documentation is required for the import process:
Valid prescription from a qualified doctor.
Patients’ diagnostic reports.
Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
Valid prescription from the doctor.
Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is NUCALA available in India?
NUCALA mepolizumab is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of NUCALA (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for NUCALA availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is mepolizumab available in India?
Sep 25, 2020 Approval FDA Approves Nucala (mepolizumab) as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand NUCALA (mepolizumab) injection. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to NUCALA (mepolizumab) injection , they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
